Abstract
Background: Autoimmune disease is a refractory disease. Accumulating Evidence has revealed that the manipulation of mesenchymal stem cells may have the potential to control or even treat autoimmune diseases. Human gingiva-derived mesenchymal stem cells (GMSCs) are emerging as a new line of mesenchymal stem cells that have displayed some potential advantages in controlling and treating autoimmune diseases.
Objective: In this review, we briefly update the current understanding on the biology of GMSCs and their effects on preventing and treating autoimmune diseases.
Conclusion: The availability of gingival mesenchymal stem cells (GMSCs), together with their potent capacity of multi-directional differentiation and inflammatory modulation, making GMSCs an ideal subtype of MSCs in treating autoimmune disease. Our and other studies have launched the earliest appraisal on GMSCs and carried out a lot of biological researches. The clinical trial of GMSCs on patients with autoimmune diseases will further approve their therapeutic effects, as well as its cellular and molecular mechanisms.
Keywords: Autoimmune diseases, mesenchymal stem cells, human gingiva-derived mesenchymal stem cells, bone marrowderived mesenchymal stem cells, cell therapy.
Current Stem Cell Research & Therapy
Title:Updates on GMSCs Treatment for Autoimmune Diseases
Volume: 13 Issue: 5
Author(s): Feng Huang, Zhong Ming Liu and Song Guo Zheng*
Affiliation:
- Department of Medicine, Milton S. Hershey Medical Center, Penn State University, Hershey, PA, 17033,United States
Keywords: Autoimmune diseases, mesenchymal stem cells, human gingiva-derived mesenchymal stem cells, bone marrowderived mesenchymal stem cells, cell therapy.
Abstract: Background: Autoimmune disease is a refractory disease. Accumulating Evidence has revealed that the manipulation of mesenchymal stem cells may have the potential to control or even treat autoimmune diseases. Human gingiva-derived mesenchymal stem cells (GMSCs) are emerging as a new line of mesenchymal stem cells that have displayed some potential advantages in controlling and treating autoimmune diseases.
Objective: In this review, we briefly update the current understanding on the biology of GMSCs and their effects on preventing and treating autoimmune diseases.
Conclusion: The availability of gingival mesenchymal stem cells (GMSCs), together with their potent capacity of multi-directional differentiation and inflammatory modulation, making GMSCs an ideal subtype of MSCs in treating autoimmune disease. Our and other studies have launched the earliest appraisal on GMSCs and carried out a lot of biological researches. The clinical trial of GMSCs on patients with autoimmune diseases will further approve their therapeutic effects, as well as its cellular and molecular mechanisms.
Export Options
About this article
Cite this article as:
Huang Feng , Liu Ming Zhong and Zheng Guo Song *, Updates on GMSCs Treatment for Autoimmune Diseases, Current Stem Cell Research & Therapy 2018; 13 (5) . https://dx.doi.org/10.2174/1574888X13666180220141114
DOI https://dx.doi.org/10.2174/1574888X13666180220141114 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
mTOR Signaling and Metabolic Regulation of T Cells: New Potential Therapeutic Targets in Autoimmune Diseases
Current Pharmaceutical Design Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Therapeutic Potential of Glycolipid Ligands for Natural Killer (NK) T Cells in the Suppression of Autoimmune Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine Targeting Cytokines of the Interleukin-12 Family in Autoimmunity
Current Medicinal Chemistry The Unique Inhibitory IgG Receptor--FcγRIIb
Protein & Peptide Letters Antibody-Mediated Endothelial Cell Damage Via Nitric Oxide
Current Pharmaceutical Design Negative Regulation of TCR Signaling in Immunological Tolerance: Taming Good and Evil
Current Immunology Reviews (Discontinued) Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews Neurological Involvement as the Initial Manifestation in Primary Sjögren's Syndrome - A Case Report
Current Rheumatology Reviews Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry The Impact of Self-Assembly in Medicine and Pharmacology
Current Pharmaceutical Analysis Generation and Characterization of a Functional Nanobody Against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Tolerance in the Absence of Autoantigen
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Secondhand Smoke on Thyroid Function
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Mechanism of the Affinity Interactions between BAFF and Its Peptides by Molecular Simulations
Protein & Peptide Letters Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets